Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis

Respiration

Volumn 95, Issue 5, 2018, Pages 317-326

  Kreuter, Michael ^a   Costabel, Ulrich ^b   Richeldi, Luca ^c   Cottin, Vincent ^d   Wijsenbeek, Marlies ^e   Bonella, Francesco ^b   Bendstrup, Elisabeth ^f   Maher, Toby M ^g   Wachtlin, Daniel ^h   Stowasser, Susanne ^h   Kolb, Martin ⁱ  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b RUHRLANDKLINIK   (Germany)

^c CATHOLIC UNIVERSITY   (Italy)

^d UNIVERSITÉ LYON 1   (France)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

^g ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^h BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

ⁱ MCMASTER UNIVERSITY   (Canada)

Author keywords

Cardiovascular diseases; Comorbidity; Forced vital capacity; Interstitial lung diseases

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NINTEDANIB; PLACEBO; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE;

ABDOMINAL PAIN; AGED; ARTICLE; BRONCHITIS; COUGHING; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PNEUMONIA; PRIORITY JOURNAL; RHINOPHARYNGITIS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VOMITING; CARDIOVASCULAR DISEASE; COMPLICATION; CONTROLLED STUDY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; VITAL CAPACITY;

AGED; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; MALE; MIDDLE AGED; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 85041536532     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000486286     Document Type: Article

References (34)

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Muller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schunemann HJ; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis: An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
2. Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A, Wirtz H, Koschel D, Andreas S, Claussen M, Grohe C, Wilkens H, Hagmeyer L, Skowasch D, Meyer JF, Kirschner J, Glaser S, Herth FJF, Welte T, Neurohr C, Schwaiblmair M, Held M, Bahmer T, Frankenberger M, Behr J: Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. Respir Res 2017; 18: 139.
3. Fernandez IE, Eickelberg O: New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet 2012; 380: 680-688.
4. Bellaye PS, Kolb M: Why do patients get idiopathic pulmonary fibrosis? Current concepts in the pathogenesis of pulmonary fibrosis. BMC Med 2015; 13: 176.
5. Hyldgaard C, Hilberg O, Bendstrup E: How does comorbidity influence survival in idiopathic pulmonary fibrosis? Respir Med 2014; 108: 647-653.
6. Kreuter M, Ehlers-Tenenbaum S, Palmowski K, Bruhwyler J, Oltmanns U, Muley T, Heussel CP, Warth A, Kolb M, Herth FJ: Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis. PLoS One 2016; 11:e0151425.
7. Noth I, Wijsenbeek M, Kolb M, Bonella F, Moros L, Wachtlin D, Corte TJ: Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS® trials (poster). American Thoracic Society International Conference, Washington, 19-24 May, 2017.
8. Raghu G, Amatto VC, Behr J, Stowasser S: Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J 2015; 46: 1113-1130.
9. O'Brien EC, Shrader P, Durheim MT, Snyder LD, Todd JL, Gamerman V, Belperio JA, Culver DA, de Andrade JAM, Roman J, Whelan TP, Conoscenti CS, Palmer SM: Disease severity and quality of life in newly diagnosed idiopathic pulmonary fibrosis patients (poster). American Thoracic Society International Conference, San Francisco, 13-18 May, 2016.
10. Jain MK, Ridker PM: Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005; 4: 977-87.
11. Liao JK, Laufs U: Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89-118.
12. Shishehbor MH, Brennan ML, Aviles RJ, Fu X, Penn MS, Sprecher DL, Hazen SL: Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 2003; 108: 426-431.
13. Schafer MJ, White TA, Iijima K, Haak AJ, Ligresti G, Atkinson EJ, Oberg AL, Birch J, Salmonowicz H, Zhu Y, Mazula DL, Brooks RW, Fuhrmann-Stroissnigg H, Pirtskhalava T, Prakash YS, Tchkonia T, Robbins PD, Aubry MC, Passos JF, Kirkland JL, Tschumperlin DJ, Kita H, LeBrasseur NK: Cellular senescence mediates fibrotic pulmonary disease. Nat Commun 2017; 8: 14532.
14. Liu S, Uppal H, Demaria M, Desprez PY, Campisi J, Kapahi P: Simvastatin suppresses breast cancer cell proliferation induced by senescent cells. Sci Rep 2015; 5: 17895.
15. Tan A, Levrey H, Dahm C, Polunovsky VA, Rubins J, Bitterman PB: Lovastatin induces fibroblast apoptosis in vitro and in vivo. A possible therapy for fibroproliferative disorders. Am J Respir Crit Care Med 1999; 159: 220-227.
16. Watts KL, Sampson EM, Schultz GS, Spiteri MA: Simvastatin inhibits growth factor expression and modulates profibrogenic markers in lung fibroblasts. Am J Respir Cell Mol Biol 2005; 32: 290-300.
17. Oka H, Ishii H, Iwata A, Kushima H, Toba S, Hashinaga K, Umeki K, Tokimatsu I, Hiramatsu K, Kadota J: Inhibitory effects of pitavastatin on fibrogenic mediator production by human lung fibroblasts. Life Sci 2013; 93: 968-974.
18. Yang T, Chen M, Sun T: Simvastatin attenuates TGF-?1-induced epithelial-mesenchymal transition in human alveolar epithelial cells. Cell Physiol Biochem 2013; 31: 863-874.
19. Fernandez AB, Karas RH, Alsheikh-Ali AA, Thompson PD: Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports. Chest 2008; 134: 824-830.
20. Xu JF, Washko GR, Nakahira K, Hatabu H, Patel AS, Fernandez IE, Nishino M, Okajima Y, Yamashiro T, Ross JC, Estepar RS, Diaz AA, Li HP, Qu JM, Himes BE, Come CE, D'Aco K, Martinez FJ, Han MK, Lynch DA, Crapo JD, Morse D, Ryter SW, Silverman EK, Rosas IO, Choi AM, Hunninghake GM; COPDGene Investigators: Statins and pulmonary fibrosis: the potential role of NLRP3 inflammasome activation. Am J Respir Crit Care Med 2012; 185: 547-556.
21. Alexeeff SE, Litonjua AA, Sparrow D, Vokonas PS, Schwartz J: Statin use reduces decline in lung function: VA Normative Aging Study. Am J Respir Crit Care Med 2007; 176: 742-747.
22. Saad N, Camus P, Suissa S, Ernst P: Statins and the risk of interstitial lung disease: a cohort study. Thorax 2013; 68: 361-364.
23. Nadrous HF, Ryu JH, Douglas WW, Decker PA, Olson EJ: Impact of angiotensin-converting enzyme inhibitors and statins on survival in idiopathic pulmonary fibrosis. Chest 2004; 126: 438-446.
24. Vedel-Krogh S, Nielsen SF, Nordestgaard BG: Statin use is associated with reduced mortality in patients with interstitial lung disease. PLoS One 2015; 10:e0140571.
25. Kreuter M, Bonella F, Maher TM, Costabel U, Spagnolo P, Weycker D, Kirchgaessler KU, Kolb M: Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis. Thorax 2017; 72: 148-153.
26. Wollin L, Wex E, Pautsch A, Schnapp G, Hostettler KE, Stowasser S, Kolb M: Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 2015; 45: 1434-1445.
27. Boehringer Ingelheim Pharmaceuticals, Inc: Ofev® (Nintedanib) Prescribing Information. 2017. http://bidocs. boehringer-ingelheim. com/BIWebAccess/ViewServlet. ser?doc Base=renetnt&folderPath=/Prescribing+ Information/PIs/Ofev/ofev. pdf (accessed April 12, 2017).
28. Boehringer Ingelheim: Ofev (Nintedanib) Summary of Product Characteristics. 2017. http://www. ema. europa. eu (accessed April 12, 2017).
29. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators: Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071-2082.
30. Costabel U, Inoue Y, Richeldi L, Collard HR, Tschoepe I, Stowasser S, Azuma A: Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. Am J Respir Crit Care Med 2016; 193: 178-185.
31. Raghu G, Crestani B, Bailes Z, Schlenker-Herceg R, Costabel U: Effect of anti-acid medication on reduction in FVC decline with nintedanib. Eur Respir J 2015; 46(suppl 59):OA4502.
32. Richeldi L, Cottin V, Flaherty KR, Kolb M, Inoue Y, Raghu G, Taniguchi H, Hansell DM, Nicholson AG, Le Maulf F, Stowasser S, Collard HR: Design of the INPULSISTM trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. Respir Med 2014; 108: 1023-1030.
33. Merck & Co, Inc: ZOCOR (Simvastatin) Prescribing Information. 2015. https://www. merck. com/product/usa/pi-circulars/z/zocor/ zocor-pi. pdf (accessed January 18, 2017).
34. Pfizer, Inc: LIPITOR® (Atorvastatin Calcium) Prescribing Information. 2015. http:// labeling. pfizer. com/ShowLabeling. aspx? id=587 (accessed 18 January 2017).